Related Experiment Video
Updated: Jul 14, 2026
08:17
A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood
Published on: February 8, 2016
10.8K
Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time
Ivan Odak1, Lâle M Bayir1,2, Lennart Riemann1,3
1Institute of Immunology, Hannover Medical School, Hannover, Germany.
Frontiers in Immunology
|February 6, 2024
Summary
CAR T-cell therapy for CD19+ B-cell malignancies shows stable activation markers, but a specific immune signature in CAR T-cell products is linked to neurotoxicity. Further phenotyping and monitoring may improve CAR T-cell therapy safety and efficacy.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- CD19 CAR T-cell therapy is a promising treatment for CD19+ B-cell malignancies.
- Understanding CAR T-cell product variability and stability is crucial for optimizing treatment success and minimizing toxicity.
- Immune cell-associated neurotoxicity syndrome (ICANS) is a significant concern in CAR T-cell therapy.
Purpose of the Study:
- To investigate the impact of CAR T-cell product characteristics on treatment outcomes and toxicity in CD19+ B-cell malignancies.
- To identify potential immune signatures associated with efficacy and adverse events, particularly ICANS.
- To explore the utility of in-depth phenotyping and longitudinal monitoring for enhancing CAR T-cell therapy.
Main Methods:
- Prospective observational study of 12 patients treated with Tisagenlecleucel.
- 31-color spectral flow cytometry to analyze CAR T-cell differentiation stages and exhaustion markers.
- Longitudinal monitoring of CAR T-cell subsets for 6 months post-infusion.
- Unsupervised cluster analysis to identify immune signatures.
Main Results:
- Most CAR T-cell activation markers exhibited stable expression patterns over time.
- Stable marker expression was not significantly associated with treatment response or toxicity.
- An immune signature within CAR T-cell products was identified and linked to the development of ICANS.
- The findings suggest a potential biomarker for predicting ICANS.
Conclusions:
- In-depth phenotyping and longitudinal monitoring of CAR T-cell products may offer valuable insights into treatment efficacy and safety.
- Identifying specific immune signatures could aid in predicting and mitigating ICANS.
- Further validation in independent cohorts is warranted to establish these findings for clinical application.
